Tarsus Pharmaceuticals, Inc.
TARS
$46.47
$2.906.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.31% | 29.65% | 6.83% | 14.73% | -7.03% |
| Total Depreciation and Amortization | 52.11% | 18.83% | -11.48% | -22.19% | 42.21% |
| Total Amortization of Deferred Charges | 6.98% | 27.72% | -11.40% | 2.70% | 9.90% |
| Total Other Non-Cash Items | -5.57% | -22.27% | 34.93% | 25.04% | -2.38% |
| Change in Net Operating Assets | -172.42% | -22.86% | 219.36% | -205.99% | -299.79% |
| Cash from Operations | -156.38% | 39.93% | 61.88% | 3.93% | -21.55% |
| Capital Expenditure | 74.47% | 72.86% | -497.13% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,844.93% | 108.64% | 61.31% | -671.71% | -62.61% |
| Cash from Investing | -2,004.54% | 107.72% | 60.36% | -672.68% | -62.32% |
| Total Debt Issued | -- | -100.00% | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 331.71% | -- | -- | 450.46% | -80.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 99.85% | -- | -- | -- |
| Cash from Financing | 358.06% | -98.49% | -61.09% | 450.46% | -81.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,513.69% | 61.26% | 59.64% | -1,711.13% | -101.44% |
